Questions Over Beta-Amyloid May Have Alzheimer's Treatment Ramifications
the Psychiatry Advisor take:
New research is questioning the shape and composition of the structures that form beta-amyloid plaque — the hallmark of Alzheimer’s disease — that could have implications for how drugs are designed that tackle the formation of the plaque.
Researchers at the Institute for Research in Biomedicine, Barcelona, Spain, examined abeta fibrils, the structures that first form in the brain when beta-amyloid protein start to clump together. More specifically, they looked at Abeta 40 and Abeta 42, the two most common forms of Abeta. Abeta 42 is the most common variant found in Alzheimer's.
Currently, Alzheimer’s researchers use a technique called SDS-PAGE to analyze the beta-amyloid clumps. But the Spanish researchers say this methodology is flawed because of incorrect conclusions it makes about the shapes of protein and the number of molecules they have.
Because of the belief that Abeta 42 formed mainly of pentamers and hexamers, it was thought that these formed "beta-sheets," which drugmakers have been focused on tackling. However, using mass spectrometry, the Spanish researchers discovered that both Abeta 40 and Abeta 42 form dimers, trimers and tetramers and that they are spherical and lack a defined structure, they reported in the journal Scientific Reports.
They add that the assumption that drugs have to interfere with the beta-sheet structure in order to target the clumping of beta-amyloid in Alzheimer’s should be reconsidered, and recommend caution when using SDS-PAGE to study Abeta.
The shape and composition of structures that make up beta-amyloid plaque is different than widely assumed with implications for drug development.
The clumping of beta-amyloid protein into plaques that clog up the brain is a key hallmark of Alzheimer's disease. Much research into the causes and treatment of the disease relies on techniques that characterize this process. Now, a new study challenges a commonly held view about the shape and composition of the initial structures that form when the beta-amyloid molecules come together.
It finds that a technique used by Alzheimer's disease researchers to analyze the beta-amyloid clumps as they initially come together is flawed because of conclusions it draws about the shapes of the aggregated proteins and the number of molecules they contain. The technique is called SDS-PAGE.
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Duration of Untreated Depression Predicts Depression Severity
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV